Japanese encephalitis virus (JEV) is a mosquito-borne flavivirus endemic to parts of Asia and the Pacific Islands [1] . Infection with JEV is usually asymptomatic, but disease presentations can range from a mild febrile syndrome with headache to severe encephalitis and death [2] . Less than 1% of JE virus infections lead to Japanese encephalitis; however, up to 20%-30% of affected patients die, whereas 30%-50% of surviving patients have associated neurologic or psychiatric morbidity [1, 3] . In endemic areas, JEV is primarily a disease of childhood. With the widespread implementation of routine JEV vaccination, rates of pediatric disease in endemic regions have declined. Despite this, the World Health Organization estimates that over 67 000 cases and 13 600-20 400 deaths occur each year [4] .
Inactivated mouse brain-derived JEV vaccines were first developed in the 1930s, with subsequent purified versions used in Japan since the 1950s. JE-VAX, a mouse brain-derived vaccine, was licensed in the United States in 1992. Adverse effects of this vaccine included severe allergic reactions and neurologic side effects, with severe local reaction reported in 20% of recipients and 10% with systemic adverse effects [2] . Since the development of JE-VAX, both live-attenuated and inactivated cell culture vaccines have been developed against JEV [5] . In 2009, an inactivated Vero cell-derived vaccine, IXIARO, was approved in the United States for patients 17 years of age and older [6] .
Because IXIARO was not approved in pediatric patients, the Advisory Committee on Immunization Practices (ACIP) recommended continued use of JE-VAX for children traveling to risk areas [7] . After existing JE-VAX doses were exhausted or expired, healthcare providers caring for children with travel to high-risk areas were left with the option of off-label use of IXIARO or enrolling children into ongoing clinical trials [8] . One pediatric clinical trial in the United States, Europe, and Australia was initiated in 2011 and has now been completed, although the results of the study have not yet been published. Preliminary data from 60 of the 100 planned subjects showed that 66.7% of subjects reported adverse events, although 60% of those events were mild. Serious or medically attended adverse events were reported in only 5% of subjects. The most frequent adverse events reported within 7 days of vaccination were injection site pain or tenderness and muscle pain [9] .
In 2013, IXIARO was approved by the US Food and Drug Administration for use in children aged 2 months to 17 years. Early clinical experience of routine use of IXIARO in children has not yet been described. For those living outside of endemic areas, travel to such areas in Asia confers risk for contracting JEV [10] . There are currently 19 military installations located in countries where disease with JEV has been identified including Cambodia, China, Japan, the Philippines, South Korea, and Vietnam among others [11] . United States military personnel are often accompanied by family members on overseas tours. Although most will reside in urban areas, the ACIP recommends immunization of long-term travelers and expatriates due to the likelihood of rural travel or sporadic epidemics of JEV. Given the need to provide the pediatric dependents of these active duty service members appropriate protection against JEV, our clinic regularly used IXIARO off-label for patients under 17 years of age after JE-VAX became unavailable. Thus, our experience provides an opportunity to evaluate the tolerability of this vaccine in routine use in a travel clinic setting. This study was designed to identify characteristics of patients, compliance with the 2-dose series, and adverse events for which parents sought medical care.
METHODS
A retrospective review of medical records from the San Antonio Military Medical Center (SAMMC) Family Travel Clinic was performed. Subjects aged 2 months to 16 years were included if they received at least 1 dose of IXIARO between November 1, 2011 and August 31, 2014. This clinic is staffed by pediatric infectious disease specialists and is the only military facility in San Antonio that routinely provides travel medicine consultation for pediatric patients and their accompanying family members. Subjects were identified by reviewing the existing paper and electronic clinic vaccination records generated at the time the vaccine was ordered by a provider and given by nursing staff. The study was approved by the Brooke Army Medical Center Institutional Review Board.
Identified subjects' electronic medical records were reviewed for any medical visit within 3 months after vaccination. Military treatment facilities use the Armed Forces Health Longitudinal Technology Application (AHLTA) as a universal electronic medical record, which permits review of outpatient records from military clinics both in the United States and overseas. In addition, the US Air Force documents all vaccinations in the Aeromedical Services Information Management System (ASIMS). Each medical encounter within 3 months of vaccination documented in AHLTA, to include those outside of our treatment facility, was recorded utilizing an electronic data collection form. The ASIMS entries were reviewed for each patient who received their initial dose of the vaccine in the SAMMC Family Travel Clinic to ensure capture of patients who received their second dose of the vaccine at an Air Force facility overseas that may not have been documented in AHLTA.
Adverse events were defined according to the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice guidelines [12] . An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A serious adverse event was defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/ birth defect. A single researcher assessed each medical event with classification as either a possible adverse event or serious adverse event, with the relationship to vaccine administration subsequently determined as probably related, possibly related, unlikely related, or not related.
RESULTS
In the study period, 92 children received 145 doses of IXIARO. Patient age ranged from 2 months to 16 years (mean = 6 years, median = 6 years). Thirty-nine subjects (42%) received 1 dose and 53 subjects (58%) received 2 doses. The majority of subjects were traveling to Japan (n = 49) or South Korea (n = 34), most commonly as part of long duration assignments of the military service member (Supplementary Table 1 ). Nine subjects were visiting friends and relatives.
Seven total adverse events (5% of doses) were documented in the 3 months after vaccination, with 6 adverse events in the 2-to 23-month age group and 1 adverse event in the 6-to 12-year age group. Three of these adverse events were directly observed by a clinic provider and 4 were by patient report only. Only 1 event, a fever that occurred 3 days after the second dose of the vaccine, was deemed to be possibly related to vaccine administration (Table 1 ). This patient also received an inactivated influenza vaccine on the same day as the IXIARO dose.
None of the other documented adverse events were serious nor were they deemed to be related to IXIARO dosing. These included a fever that developed 36 days after administration of dose number 2, a fever in the setting of an acute otitis media infection 27 days after vaccination, a cough that developed 15 days after vaccination, a fever in the setting of an upper respiratory infection 79 days after vaccination, a cough that developed 37 days after administration of dose number 2, and a cough in the setting of an upper respiratory infection 60 days after dosing. None of these children required hospitalization.
Vaccinations have long been the standard of care for prevention of disease. Although vaccine safety is often a topic of debate, the medical literature clearly supports their routine use. A recent review article published in Pediatrics examining the safety of routine vaccinations in children less than 6 years of age demonstrated that although evidence was found of serious adverse events related to routine vaccinations, these instances were extremely rare [13] . Such large-scale studies are difficult to perform for vaccines that are only used in small at-risk groups, such as the JEV vaccine.
Immunization against JEV is recommended for long-term travelers to endemic areas to prevent rare but serious disease associated with infection. There was a high adverse event profile with JE-VAX, and although several newer vaccines for JEV with better safety profiles had been developed, there was no alternative option for pediatric patients in the United States until IXIARO was approved in 2013. IXIARO has been associated with a low rate of adverse events in postmarketing data [14] . A review of the US Vaccine Adverse Event Reporting System for adults greater than or equal to 17 years of age who received IXIARO from May 2009 through April 2012 showed an adverse event rate of 15.2 per 100 000 doses administered with a serious adverse event rate of 1.8 per 100 000 doses administered [15] .
Although postmarketing data regarding IXIARO in pediatric patients remains limited, the previously mentioned clinical trial reported 66.7% of pediatric recipients had 1 or more adverse events with 5% requiring additional medical care. Compared to this single preliminary report, our review found far less adverse events than expected. As a retrospective study, our review was not designed to detect minor events that did not come to medical attention. However, such events are unlikely to be of significant concern to prescribing providers. Overall, this review shows that serious adverse events requiring medical care are uncommon and reinforces the tolerability of this vaccine in the pediatric age group. Because it has been demonstrated that perceived vaccine safety is a significant predictor of compliance with JEV vaccine administration [16] , providers, patients, and patient families can be reassured by the results of our review.
Maximizing compliance with vaccinations and other recommendations is a significant focus in a travel clinic setting. Our clinic provides intensive counseling regarding all travel risks and the various ways to mitigate those risks, to include completion of all recommended vaccines. In addition, walk-in appointments for subsequent doses are scheduled during the initial visit while allowing families the flexibility of rescheduling this appointment with a single phone call. Despite these efforts to maximize both education and convenience in a system providing immunization at no direct financial cost to the patient, overall compliance with the 2-dose series in our population was only 58%. As of February 1, 2015, JEV vaccine was required for all active duty Air Force personnel assigned to Japan or Korea, as well as for those deploying to areas deemed to have an increased risk for Japanese encephalitis. Vaccination was encouraged for all dependents already living in or scheduled to be moving to Japan or Korea with the active duty member [17] . Despite this recommendation, compliance with completing the vaccination series has remained poor. As of July 2015, in 9238 Air Force beneficiaries <17 years of age residing in Korea and Japan, 15% received at least 1 dose and only 9% received 2 doses (R. Hall, unpublished data). Further investigation into the specific factors contributing to this noncompliance is warranted in order to improve these numbers.
Our study was limited by its retrospective nature. We focused solely on chart review to determine adverse events, and thus we were unable to identify minor events that caregivers did not believe warranted further evaluation or medical care. The military medical system design, which allows no cost, universal access to care across any treatment facility regardless of geographic location, along with a common medical record system makes it likely that we captured most, if not all, visits made by our subjects in the time window studied.
CONCLUSIONS
Our study's confirmation of IXIARO's tolerability in a pediatric population reinforces the recent decision to expand its use into this younger age group. Our data support this recommendation in a real-life clinical practice. Practitioners should feel comfortable universally recommending vaccination against JEV for any pediatric traveler to an area of risk, and they can reassure families about the vaccine's tolerability.
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